This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CYCC Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisDividendEarningsFDA EventsHeadlinesInsider TradesTrendsBuy This Stock About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC) Get CYCC alerts:Sign Up Key Stats Today's Range$6.37▼$6.3750-Day Range$6.36▼$9.2852-Week Range$0.22▼$19.87VolumeN/AAverage Volume3.54 million shsMarket Capitalization$14.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapies that target key mechanisms of cell division. Founded in 1996, the company has built a pipeline of experimental small-molecule inhibitors designed to disrupt the activity of cyclin-dependent kinases (CDKs) and other cell cycle regulators. These targeted agents are intended to selectively halt the proliferation of tumor cells while minimizing effects on healthy tissue. The company’s most advanced programs include fadraciclib (formerly CYC065), an oral CDK2/9 inhibitor in Phase 1/2 studies for advanced solid tumors and hematologic malignancies, and CYC140, a novel allosteric inhibitor of aurora kinases under early clinical evaluation. Cyclacel’s research and development efforts leverage in-house discovery platforms as well as strategic collaborations with academic institutions and contract research organizations. This collaborative model supports rapid translation of laboratory findings into clinical candidates. Cyclacel is headquartered in Berkeley Heights, New Jersey, with additional research operations in Dundee, Scotland, reflecting its UK-US footprint. Over the years, the company has advanced multiple compounds into human trials, demonstrating its ability to move promising molecules through preclinical stages. Under its experienced management team, Cyclacel continues to explore combination regimens and biomarker-driven approaches to enhance the therapeutic potential of its pipeline agents for patients with hard-to-treat cancers.AI Generated. May Contain Errors. Read More Receive CYCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYCC Stock News HeadlinesCyclacel Pharmaceuticals Implements Reverse Stock Split in JulyAugust 14, 2025 | msn.comCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateAugust 13, 2025 | globenewswire.comMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson says what's unfolding in New York City is just the beginning. Tilson, a Harvard MBA who spent 30 years on Wall Street, has identified a specific economic pattern he believes points to a financial reset unlike anything seen in over 100 years. He's released a free analysis outlining what's coming and the exact steps he recommends you take with your money now.June 24 at 1:00 AM | Stansberry Research (Ad)CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIBAugust 4, 2025 | globenewswire.comCYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITYJuly 16, 2025 | finance.yahoo.comCyclacel stock dips after trimming 270% surge amid volatility concernsJuly 16, 2025 | msn.comWhy Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?July 15, 2025 | benzinga.comWhy Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?July 15, 2025 | benzinga.comSee More Headlines CYCC Stock Analysis - Frequently Asked Questions How were Cyclacel Pharmaceuticals' earnings last quarter? Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its earnings results on Wednesday, August, 13th. The biotechnology company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($72.00) by $71.02. When did Cyclacel Pharmaceuticals' stock split? Shares of Cyclacel Pharmaceuticals reverse split on Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Cyclacel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET). Company Calendar Last Earnings8/13/2025Today6/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYCC CIK1130166 Webwww.cyclacel.com Phone(908) 517-7330Fax866-271-3466Employees14Year Founded1992Profitability EPS (Trailing Twelve Months)($839.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.21 million Net MarginsN/A Pretax Margin-54,220.00% Return on Equity-723.64% Return on Assets-145.51% Debt Debt-to-Equity RatioN/A Current Ratio5.77 Quick Ratio5.77 Sales & Book Value Annual Sales$40 thousand Price / Sales356.44 Cash FlowN/A Price / Cash FlowN/A Book Value($58.87) per share Price / Book-0.11Miscellaneous Outstanding Shares2,240,000Free Float1,093,000Market Cap$14.26 million OptionableOptionable Beta0.15 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CYCC) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredEvery time Musk needs a company, he buys itMusk needed batteries - he built the Gigafactory. Needed solar - acquired SolarCity. Needed data - bought Twit...Behind the Markets | SponsoredFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
